Fig. 3From: Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitorsInfluence of baseline proinflammatory markers on overall survival (OS) of patients who were readministered with tyrosine kinase inhibitors (a) OS between patients with high and low baseline neutrophil-to-lymphocyte ratio (NLR); (b) OS between patients with high and low lymphocyte-to-monocyte ratio (LMR)Back to article page